Teva Pharmaceutical Industries L (NYSE: TEVA). Meaningful negative changes in fundamentals have recently occurred: significant quarterly sales deceleration occurred, the consensus estimate for December, 2025 decreased significantly, and the consensus estimate for December, 2026 decreased significantly.
Significant negative changes in investment behavior have recently occurred for Teva Pharmaceutical Industries L (NYSE: TEVA): its shorter term price trend turned down.
In light of these highly negative signals we are reviewing our current Overall Rating of B. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Teva Pharmaceutical Industries L has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Teva Pharmaceutical Industries L has a neutral Power Rating of 57 but a good Appreciation Score of 74, resulting in the Positive Value Trend Rating.
Recent Price Action
Teva Pharmaceutical Industries L (NYSE: TEVA) stock declined by -2.7% on 2/7/25. The shares closed at $16.83. NORMAL trading volume accompanied the decline. The stock has been strong relative to the market over the last nine months but has declined -5.7% during the last week.
Be the first to comment